Gastric Inhibitory Polypeptide (GIP) Antibody
273€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Gastric Inhibitory Polypeptide (GIP) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx131964
tested applications
WB, IHC, IF/ICC
Description
Gastric Inhibitory Polypeptide Antibody is a Mouse Monoclonal against Gastric Inhibitory Polypeptide.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Gastric Inhibitory Polypeptide (GIP) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | IHC: 5-30 µg/ml, IF/ICC: 5-30 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG2a Lambda |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P09681 |
| Alias | Glucose-dependent insulinotropic polypeptide,Incretin |
| Background | Antibody anti-GIP |
| Status | RUO |
Descripción
GIP, also called glucose-dependent insulinotropic polypeptide, is a 42-amino acid hormone secreted by K-cells in the duodenum and jejunum in response to nutrient ingestion, particularly glucose, fats, and amino acids GIP acts as a critical incretin hormone that enhances glucose-dependent insulin secretion from pancreatic β-cells by activating cAMP-dependent pathways and protein kinase A signaling GIP also regulates lipid metabolism by stimulating lipoprotein lipase activity in adipose tissue, promoting triglyceride uptake and energy storage GIP further supports bone homeostasis by enhancing osteoblast function, contributing to bone formation and mineralization Dysregulation of GIP levels and signaling is associated with insulin resistance, obesity, and type 2 diabetes where its insulinotropic effects are impaired despite elevated circulating levels GIP-based therapies, including dual GIP/GLP-1 receptor agonists, have shown therapeutic potential in improving glycemic control and promoting weight loss in metabolic disorders
Related Products
Human GIP(Gastric inhibitory polypeptide) ELISA Kit
Ver Producto
Mouse Gip(Gastric inhibitory polypeptide) ELISA Kit
Ver Producto